Liraglutide vs FGL
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →FGL
FGL (FG Loop) is a synthetic peptide that mimics the neural cell adhesion molecule (NCAM) FG loop region. It promotes neuroplasticity and has shown cognitive-enhancing effects in research.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | FGL |
|---|---|---|
| Mechanism | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. | Binds to FGFR1 (fibroblast growth factor receptor 1) to activate downstream signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival. |
| Typical Dosage | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. | Research protocols have used subcutaneous doses ranging from 1-10mg. Intranasal administration also studied. Optimal dosing not established. |
| Administration | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. | Subcutaneous injection or intranasal administration. Research compound with limited human dosing data. |
| Side Effects | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. | Limited human data available. Animal studies show good tolerability. |
| Best For |